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Abstract: Background and objectives: Malignant pleural mesothelioma (MPM) is a devastating
malignancy with poor prognosis. Reliable biomarkers for MPM diagnosis, monitoring, and prognosis
are needed. The aim of this study was to identify genes associated with wound healing processes whose
expression could serve as a prognostic factor in MPM patients. Materials and Methods: We used data
mining techniques and transcriptomic analysis so as to assess the differential transcriptional expression
of wound-healing-associated genes in MPM. Moreover, we investigated the potential prognostic
value as well as the functional enrichments of gene ontologies relative to microRNAs (miRNAs)
of the significantly differentially expressed wound-healing-related genes in MPM. Results: Out of
the 82 wound-healing-associated genes analyzed, 30 were found significantly deregulated in MPM.
Kaplan–Meier analysis revealed that low ITGAV gene expression could serve as a prognostic factor
favoring survival of MPM patients. Finally, gene ontology annotation enrichment analysis pointed
to the members of the hsa-miR-143, hsa-miR-223, and the hsa-miR-29 miRNA family members as
important regulators of the deregulated wound healing genes. Conclusions: 30 wound-healing-related
genes were significantly deregulated in MPM, which are potential targets of hsa-miR-143, hsa-miR-223,
and the hsa-miR-29 miRNA family members. Out of those genes, ITGAV gene expression was a
prognostic factor of overall survival in MPM. Our results highlight the role of impaired tissue repair
in MPM development and should be further validated experimentally.
Keywords: in silico; malignant pleural mesothelioma; miRNA; transcriptomics; wound healing
1. Introduction
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor of the pleural mesothelium,
a metabolically active cell monolayer covering the lungs and the chest wall [1]. Neoplastic
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transformation of pleural mesothelial cells (PMCs) develops in the course of asbestos-induced chronic
inflammation while genetic susceptibility factors, radiation exposure, and SV40 infection have also
been indicated as co-factors in this process [2,3]. Recent evidence from animal studies and a few case
series show that engineered nanoparticles, whose use is constantly expanding, can lead to a pathology
similar to MPM and, thus, potentially lead to an increase of MPM incidence in the future and the same
is the case with air pollution, which has been shown to lead to lung cancer [4,5].
Diagnosis of MPM is challenging mainly because the pleura is a common site for metastasis and
reactive, benign changes observed in the pleural space may be confused with MPM [6]. At the same
time, prognosis is poor since MPM therapeutic management depends on patient performance status,
which is usually not good due to late diagnosis, and is potentially effective mostly in the epitheliod
subtype [7]. For these reasons, the availability of effective bio markers is necessary for three clinical
aspects of MPM: Early diagnosis, prognosis, and treatment outcome prediction [8].
Aberrant inflammation that could occur during wound healing has been linked to the pathogenesis
of a variety of malignancies [9,10]. Environmental and infectious agents are considered key players
during carcinogenesis development as they conduce to tissue damage and inflammatory reactions [9].
In the case of MPM, asbestos-induced chronic inflammation—mainly due to the production of reactive
oxygen/nitrogen species—results in decreased tumor immunity [11]. Location and inflammatory
response type impact on the overall prognosis of MPM patients [9].
PMCs hold a central role in the initiation and resolution of serosal inflammation and repair by
secreting various pro- and anti- inflammatory mediators along with immunomodulatory ones [12,13].
It is worth noting that mesothelial regeneration of injured mesothelial surfaces appears diffusely across
the traumatized area in contrast to epithelial-like surfaces, in which healing occurs solely from the
wound edges [12]. Mesothelial injury and impaired healing can lead to the development of pleural
effusions, serosal adhesions, and malignant mesothelioma [13,14]. Several studies have confirmed that
following damage, mesothelial cells undergo mesothelial-to-mesenchymal transition (MMT), a process
similar to epithelial-to-mesenchymal transition (EMT) [15]. It has been reported that the aggressiveness
of MPM may be explained by its partial fibroblastic phenotype in the context of EMT conferring both
high invasiveness and chemoresistance [16].
Although the above observations highlight the importance of normal serosal repair following injury,
a thorough investigation of the exact role of wound-healing-associated genes in MPM development
has not been performed [15]. Research in this direction is even more imperative nowadays due to the
wide use of nanoparticles in a variety of applications since nano-sized fibrous particulates have similar
properties to asbestos thus raising safety concerns for human health [17,18].
Here, we aimed at the identification of the differential expression of wound-healing-associated
genes in MPM. For this purpose, we used established data mining techniques and transcriptomic
analysis [19–22]. Moreover, we investigated their potential prognostic value as well as the functional
enrichments of gene ontologies (GO) relative to the microRNAs (miRNAs) that regulate the significantly
differentially expressed wound-healing-related genes in MPM.
2. Materials and Methods
2.1. Transcriptomic Analysis of Wound-Healing-Associated Genes in MPM
The Oncomine Cancer Microarray database Premium Research Edition (http://www.oncomine.org)
was used to investigate the expression profile of wound-healing-associated genes in MPM compared
with healthy controls. Gene expression data from the GDS1220 dataset of GEO Profiles were used in
which the Affymetrix Human Genome U133A array was used assessing 12,624 genes [23]. We analyzed
available data for 82 wound-healing-related genes (from the according list of genes included in the
Wound Healing RT2 Profiler PCR Arrays from Qiagen) that were assessed in the GDS1220 study
(Table 1), so as to detect gene expression differences between MPM specimens and healthy controls [23].
The raw data were downloaded in Excel format from Oncomine and only the ones referring to surgically
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excised samples were selected, leading to the use of n = 40 MPM cases and n = 9 controls (n = 5 pleura
and n = 4 lung samples). The gene expression data were log transformed, median centered per array,
and the standard deviation was normalized to one per array as described previously [24].
Table 1. The wound-healing-associated genes investigated in this study.
Hugo Gene Nomenclature Committee Gene Name. Gene Description
ITGA3 Integrin Subunit Alpha 3
ITGAV Integrin Subunit Alpha V
ITGB6 Integrin Subunit Beta 6
RAC1 Ras-Related C3 Botulinum Toxin Substrate 1 (RhoFamily, Small GTP Binding Protein Rac1)
COL5A1 Collagen Type V Alpha 1 Chain
COL5A2 Collagen Type V Alpha 2 Chain
ANGPT1 Angiopoietin 1
COL1A1 Collagen Type I Alpha 1 Chain
COL3A1 Collagen Type III Alpha 1 Chain
CSF3 Colony Stimulating Factor 3
HBEGF Heparin Binding EGF Like Growth Factor
MIF Macrophage Migration Inhibitory Factor(Glycosylation-Inhibiting Factor)
TGFA Transforming Growth Factor Alpha
TNF Tumor Necrosis Factor
VTN Vitronectin
CXCL2 C-X-C Motif Chemokine Ligand 2
CXCL5 C-X-C Motif Chemokine Ligand 5
IL6 Interleukin 6
IL10 Interleukin 10
PTGS2 Prostaglandin-Endoperoxide Synthase 2
MAPK3 Mitogen-Activated Protein Kinase 3
PTEN Phosphatase And Tensin Homolog
IL6ST Interleukin 6 Signal Transducer
STAT3 Signal Transducer And Activator Of Transcription 3
TGFBR3 Transforming Growth Factor Beta Receptor 3
CTSG Cathepsin G
F3 Coagulation Factor III, Tissue Factor
F13A1 Coagulation Factor XIII A Chain
PLAUR Plasminogen Activator, Urokinase Receptor
PLG Plasminogen
SERPINE1 Serpin Family E Member 1
TIMP1 IMP Metallopeptidase Inhibitor 1
COL1A2 Collagen Type I Alpha 2 Chain
ITGB3 Integrin Subunit Beta 3
ITGB5 Integrin Subunit Beta 5
COL5A3 Collagen Type V Alpha 3 Chain
VEGFA Vascular Endothelial Growth Factor A
WNT5A Wnt Family Member 5A
WISP1 WNT1 Inducible Signaling Pathway Protein 1
CTNNB1 Catenin Beta 1
MAPK1 Mitogen-Activated Protein Kinase 1
EGFR Epidermal Growth Factor Receptor
TGFB1 Transforming Growth Factor Beta 1
CDH1 Cadherin 1
ITGA1 Integrin Subunit Alpha 1
ITGA2 Integrin Subunit Alpha 2
ITGA4 Integrin Subunit Alpha 4
ITGA5 Integrin Subunit Alpha 5
ITGA6 Integrin Subunit Alpha 6
ITGB1 Integrin Subunit Beta 1
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Table 1. Cont.
Hugo Gene Nomenclature Committee Gene Name. Gene Description
ACTA2 Actin, Alpha 2, Smooth Muscle, Aorta
ACTA1 Actin, Alpha 1, Skeletal Muscle
RHOA Ras Homolog Family Member A
TAGLN Transgelin
COL4A1 Collagen Type IV Alpha 1 Chain
COL4A3 Collagen Type IV Alpha 3 Chain
COL14A1 Collagen Type XIV Alpha 1 Chain
CTSK Cathepsin K
CTSL2 cathepsin L2
FGA Fibrinogen Alpha Chain
MMP1 Matrix Metallopeptidase 1
MMP2 Matrix Metallopeptidase 2
MMP7 Matrix Metallopeptidase 7
MMP9 Matrix Metallopeptidase 9
PLAT Plasminogen Activator, Tissue Type
PLAU Plasminogen Activator, Urokinase
CSF2 Colony Stimulating Factor 2
CTGF Connective Tissue Growth Factor
EGF Epidermal Growth Factor
FGF2 Fibroblast Growth Factor 2
FGF7 Fibroblast Growth Factor 7
HGF Hepatocyte Growth Factor
IGF1 Insulin Like Growth Factor 1
PDGFA Platelet Derived Growth Factor Subunit A
CCL2 C-C Motif Chemokine Ligand 2
CCL7 C-C Motif Chemokine Ligand 7
CD40LG CD40 Ligand
CXCL1 C-X-C Motif Chemokine Ligand 1
CXCL11 C-X-C Motif Chemokine Ligand 11
IL1B Interleukin 1 Beta
IL2 Interleukin 2
IL4 Interleukin 4
2.2. Evaluation of the Significantly Differentially Expressed Wound-Healing-Related Genes for Prognostic Relevance
We investigated the prognostic relevance of the significantly differentially expressed
wound-healing-related genes by creating survival curves, using the publicly available survival
data of each patient from the GDS1220 study. Patients were grouped as high expressing (above median)
and low expressing (below median) per each significantly differentially expressed gene based on the
median value of gene expression. To further evaluate the prognostic significance of the genes that were
identified in the analysis of the GDS1220 mesothelioma study, we constructed survival curves from
data derived from The Cancer Genome Atlas (TCGA). For this analysis, we used the PROGgeneV2
Prognostic Database software following the same approach used previously [25].
2.3. Functional Annotation Enrichment Gene Ontology Analysis of the miRNAs That Regulate the
Significantly Differentially Expressed Wound-Healing-Related Genes in MPM
Functional annotation enrichment analysis of GO relative to Biological Functions and miRNAs
was performed, assuming the statistical background of the whole genome. The complete list of
the significantly differentially expressed wound-healing-related genes was introduced to the portal
ToppFun, an application of the ToppGene Suite (https://toppgene.cchmc.org/). ToppFun reports functional
enrichment of input gene lists based on transcriptome (gene expression), proteome (protein domains
and interactions), regulome (transcription factor binding sites and miRNA), ontologies (GO, pathway),
phenotype (human disease and mouse phenotype), pharmacome (drug–gene associations), and bibliome
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(literature co-citation) [26]. Functional enrichments are provided by the ToppFun algorithm, which
employs hypergeometric distribution with multiple correction testing (false discovery rate; FDR) to
determine statistical significance. Analysis was performed during February 2019.
2.4. Statistical Analysis
The results were analyzed using GraphPad Prism 8.0 (GraphPad Software, San Diego, CA) and R
3.3.2 [27]. Data distribution was tested by the Kolmogorov–Smirnov normality test. Comparisons of gene
expressions were performed with the one-tailed t-test for parametric data and the Mann–Whitney U-test
for nonparametric data. The Benjamini–Hochberg FDR was employed for multiple correction testing,
which reports FDR (or q-value), in order to corroborate the validity of the results. The calculation of the
q statistic was based on the formula Q = P value × total number of genes/P-value rank [24]. Statistical
significance was set at the q < 0.05 level. Kaplan–Meier survival curves were generated using the overall
survival data of the MPM patients and by grouping them into high and low gene expressions based on the
median. The log-rank (Mantel–Cox) test, which gives equal weight to deaths at all time points, was used.
Differences were deemed significant with a p ≤ 0.05. A multivariate regression was performed using the
initial dataset of 30 differentially expressed genes where the ITGAV gene expression was chosen as the
dependent variable. At first, all predictors were considered, and a model was derived. This mode had an
acceptable R2 value but had to be discarded since the predictors were over-fit. Next, a backwards method
was implemented that takes into consideration the Variance Inflation Factor (VIF) value of each predictor.
If VIF of an independent variable exceeded the predetermined threshold value of 5, that predictor was
discarded from the model. Thus, one avoids multi-collinearity in a model but may still obtain an overfitted
model. To avoid this, an additional backwards step-wise regression was performed on the surviving
variable so as to have a robust final model.
3. Results
3.1. Identification of the Differential Transcriptional Expression Of Wound-Healing-Associated Genes in MPM
Out of the 82 wound-healing-related genes analyzed, 30 were found significantly differentially
expressed in MPM (14 up-regulated/16 down-regulated, results summarized in Table 2). Ten genes
(ITGB3, ITGB5, COL5A3, VEGFA, WNT5A, WISP1, CTNNB1, F13A1, PLAUR, TIMP1) were found
significantly deregulated in the initial mean value comparison test (p = 0.008, p = 0.023, p = 0.016,
p = 0.0115, p = 0.0205, p = 0.0055, p = 0.024, p = 0.0445, p = 0.0405, p = 0.046, respectively) but not after
the multiple correction testing (q = 0.055, q = 0.1649, q = 0,128, q = 0.1905, q = 0.314, q = 0.055, q = 0.133,
q = 0.1898, q = 0.1789, q = 0.1375, respectively).







COL5A1 1.29 × 10−3 3.4584
COL5A2 1.06 × 10−3 3.7013
COL1A1 1.24 × 10−3 2.6257
COL3A1 2.79 × 10−3 4.0285
MIF 8.36 × 10−3 2.8341
VTN 4.55 × 10−3 7.1654
MAPK3 1.24 × 10−3 2.4605
IL6ST 0.0149 1.6038
STAT3 2.51 × 10−3 2.9051












CXCL2 3.86 × 10−3 −4.6691
CXCL5 8.40 × 10−4 −2.1452
IL6 0.01932 −6.2047
IL10 0.039 −1.3583
PTGS2 7.29 × 10−4 −4.408
PTEN 0.033 −1.407
TGFBR3 2.14 × 10−3 −2.0823
CTSG 2.08 × 10−3 −2.5715
F3 0.03 −2.3331
PLG 0.027 −1.5597
3.2. Prognostic Significance of ITGAV Gene Expression in MPM
Kaplan–Meier analysis of the significantly deregulated wound-healing-related genes in MPM
identified the ITGAV gene expression as a predictor of overall survival. Graphical representation of the
ITGAV gene expression from the GDS1220 study is shown in Figure 1A. In the GDS1220 study, MPM
patients with low ITGAV expression had a median overall survival of 15.7 months versus 12 months of
those that had high expression (p = 0.0263) (Figure 1B). Analysis from the TCGA patient data derived
from the PROGgeneV2 database corroborates that low ITGAV gene expression favors survival in MPM
patients (p = 0.001) (Figure 2).
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Figure 1. (A) Violin plot of the ITGAV gene expression shows that it is significantly overexpressed in
MPM patients compared to controls. (B) Low ITGAV gene expression in MPM patients favors their
survival (shown in months).
Medicina 2019, 55, 267 7 of 12
Medicina 2019, 55, x FOR PEER REVIEW 7 of 13 
 
 
Figure 2. Results of Kaplan–Meier survival analysis from The Cancer Genome Atlas (TCGA) 
mesothelioma dataset derived from PROGgeneV2 database, shows that low ITGAV gene expression 
favors survival (shown in days) in MPM patients. 
3.3. Statistical Modeling Reveals A Positive Correlation of ITGAV and COL5A1 Gene Expressions 
Multivariate regression was performed as shown in Table 3, and the following model was 
obtained using backwards selection methods: 
ITGAV = 1.89725 + 0.41537 COL5A1 (1) 
Table 3. Statistical modeling of the correlation of ITGAV and COL5A1 gene expressions. 
Coefficients Estimate Std. Error T Value Pr(>|t|) 
(Intercept) 1.89725 0.20885 9.084 4.59e–11*** 
COL5A1 0.41537 0.07451 5.574 2.18e–06*** 
The model explains the 43.54% (adjusted R2 = 0.4354) of the variability of the response data 
around its mean. F-statistic and p-value indicate that the model is significant for the explanation of 
the variability of the response data. The coefficients of the model are positive, hence whenever the 
value of COL5A1 increases, the same happens to the value of ITGAV. The value of each coefficient 
shows the increase of the value of ITGAV if the corresponding variable is increased or decreased by 
one unit, while the rest remain fixed. 
3.4. Enriched Gene Ontologies (GO) Relative To Regulating miRNAs of the Significantly Differentially 
Expressed Wound-Healing-Associated Genes In MPM 
The complete set of the significantly differentially expressed wound-healing-associated genes 
was entered in the ToppFun software. The top five enriched GO for biological functions are presented 
in Table 4, and the miRNAs that regulate the differentially expressed genes are shown in Table 5. 
Table 4. Functional enrichment analysis relative to Biological Functions of the wound-healing-
associated genes differentially expressed in MPM patients.* 








1 GO:0040011 locomotion 2.531E-23 7.177E-20 6.120E-19 7.177E-20 26 1735 
Figure 2. Results of Kaplan– eier survival analysis from The Cancer Genome Atlas (TCGA)
mesothelioma dataset derived from PROGgeneV2 database, shows that low ITGAV gene expression
favors survival (shown in days) in MPM patients.
3.3. Statistical Modeling Reveals A Positive Correlation of ITGAV and COL5A1 Gene Expressions
Multivariate regression was performed as shown in Table 3, and the following model was obtained
using backwards selection methods:
ITGAV = 1.89725 + 0.41537 COL5A1 (1)
able 3. Statistical o eling of the correlation of IT V and COL5A1 gene expressions.
Coefficients Estimate Std. rr r T l Pr (>|t|)
(Intercept) 1.89725 0.20885 9.084 4.59 × 10−11 ***
COL5A1 0.41537 0.07451 5.574 2.18 × 10−6 ***
The model explain the 43.54% (adjusted R2 = 0.4354) of the variab lity of the respo se data
aro nd its mean. F-statistic and p-value indicate tha the model is significant for th explanati n of the
variability of th response data. The coefficien s of the model are positive, hence wh never the value of
COL5A1 increases, the sa e happ ns to the value of ITGAV. The value of each coefficient shows the
increase of the value of ITGAV if the corresponding variable is increased or decreased by one unit,
while the rest remain fixed.
3.4. Enriched Gene Ontologies (GO) Relative To Regulating miRNAs of the Significantly Differentially
Expressed Wound-Healing-Associated Genes In MPM
The complete set of the significantly differentially expressed wound-healing-associated genes was
entered in the ToppFun software. The top five enriched GO for biological functions are presented in
Table 4, and the miRNAs that regulate the differentially expressed genes are shown in Table 5.
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Table 4. Functional enrichment analysis relative to Biological Functions of the wound-healing-associated genes differentially expressed in MPM patients *.





1 GO:0040011 locomotion 2.531 × 10−23 7.177 × 10−20 6.120 × 10−19 7.177 × 10−20 26 1735
2 GO:0016477 cell migration 5.798 × 10−23 1.644 × 10−19 24 1300
3 GO:0051674 localization of cell 5.395 × 10−22 3.825 × 10−19 3.262 × 10−18 1.530 × 10−18 24 1428
4 GO:0048870 cell motility 5.395 × 10−22 3.825 × 10−19 3.262 × 10−18 1.530 × 10−18 24 1428
5 GO:0030334 regulation of cell migration 1.635 × 10−21 9.274 × 10−19 7.909 × 10−18 4.637 × 10−18 20 742
* Results were obtained through ToppFun, an application of the ToppGene suite (https://toppgene.cchmc.org/). FDR: False discovery rate; B&H: Benjamini–Hochberg; B&Y:
Benjamini–Yekutieli. Only the top five results are presented.
Table 5. Functional enrichment analysis relative to miRNAs of the wound-healing-associated genes differentially expressed in MPM patients *.





1 hsa-miR-143-3p:FunctionalMTI Functional MTI miRTarbase 5.442 × 10
−12 1.459 × 10−8 1.236 × 10−7 1.459 × 10−8 7 228
2 hsa-miR-223-3p:FunctionalMTI Functional MTI miRTarbase 5.747 × 10
−10 7.704 × 10−7 6.526 × 10−6 1.541 × 10−6 5 98
3 hsa-miR-29b-3p:FunctionalMTI Functional MTI miRTarbase 1.159 × 10
−9 1.036 × 10−6 8.776 × 10−6 3.108 × 10−6 6 261
4 hsa-miR-29a:PITA hsa-miR-29a:PITATOP PITA 3.728 × 10
−9 1.666 × 10−6 1.411 × 10−5 9.995 × 10−6 7 583
5 hsa-miR-29c:PITA hsa-miR-29c:PITATOP PITA 3.728 × 10
−9 1.666 × 10−6 1.411 × 10−5 9.995 × 10−6 7 583
* Results were obtained through ToppFun, an application of the ToppGene suite (https://toppgene.cchmc.org/). FDR: False discovery rate; B&H: Benjamini–Hochberg; B&Y:
Benjamini–Yekutieli. Only the top five results are presented.
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4. Discussion
Chronic tissue repair and insistent immune system stimulation following the accumulation of
inhaled asbestos fibers in the pleural space are key oncogenic processes during MPM development [28].
In this study, we used transcriptome data mining in order to assess the differential mRNA expression
of wound-healing-related genes in MPM. We analyzed available data for 82 genes, of which 30
were found significantly deregulated in MPM specimens compared with healthy tissues. Identified
genes are mainly involved in inflammation (CXCL2, CXCL5, IL6, IL10), cellular adhesion (ITGA3,
ITGAV, ITGB6), tissue remodeling (CTSG, F3, PLG, SERPINE1), and extracellular matrix organization
(COL1A1, COL3A1, COL5A1, COL5A2, CSF3, HBEGF, MIF, TGFA, VTN), fundamental processes in
the induction of EMT and cancer progression [29–32]. A recent study has suggested that asbestos
induces mesothelial-to-fibroblastic transition in an inflammasome-dependent manner and this seems
to apply for other pathogenic particles as well [28,33,34].
The acquisition of a mesenchymal phenotype by PMCs has been correlated with the sarcomatoid
histological type of MPM, the latter being associated to worse prognosis [16,35]. It has been suggested
that in MPM patients with sarcomatoid histology, radical surgery should be excluded, and therapy
should aim at symptom control and preservation of quality of life [36]. Considering the importance
of clear histological subtype distinction in the initiation of the appropriate therapeutic intervention,
it would be of great interest to investigate the transcriptional expression of the 30 significantly
deregulated genes—identified in this study—with respect to the MPM phenotype [22]. Unfortunately,
data relative to the histological subtype of MPM specimens were not available in the GDS1220
mesothelioma study.
Among the 30 significantly differentially expressed wound-healing-associated genes in MPM,
ITGAV was identified as a predictor of overall survival in patients suffering from this type of cancer.
In the transcriptomic analysis, ITGAV was found significantly up-regulated in MPM subjects compared
with healthy controls, and survival analysis revealed that low ITGAV gene expression favors the survival
of MPM patients. In accordance with our results, recent studies have reported the tumor-promoting
effect of ITGAV via the furtherance of the EMT process [37,38]. The gene expression level of the
ITGAV integrin has also been associated with global survival in patients with colorectal cancer, both in
univariate and multivariate analyses [39].
Following the above findings, our regression modelling predicted a significant positive correlation
in the expression profiles of the ITGAV and COL5A1 genes. The latter encodes the a1 chain of type
V collagen, a fibril-forming collagen that is mainly distributed in the lung, cornea, bone, and fetal
membranes, together with type I collagen [40,41]. Interestingly, COL5A1 has been included in a
10-gene signature that is associated with poor survival both in patients with high-grade serous ovarian
cancer and renal cell carcinoma [42,43].
Finally, the biological functions mediated by the differentially regulated genes as revealed by the
GO functional enrichment analysis were pertinent to wound healing functions, such as cell locomotion,
mobility, and migration. Furthermore, the GO annotation enrichment analysis predicted that the
30 wound-healing-related genes that were found significantly deregulated in MPM might be targets
of the hsa-miR-143, hsa-miR-223, and the hsa-miR-29 miRNA family members. MicroRNAs have
emerged as significant players in the biology of MPM, whilst miRNA-based therapy for the treatment
of MPM has been suggested as an exciting area of research [44]. The hsa-miR-29c has been identified
as an epigenetic regulator in MPM via the down-regulation of DNA methyltransferases and the
up-regulation of demethylating genes [45]. In addition, increased expression of this miRNA has
been linked to a more favorable prognosis in MPM [45]. On the other hand, hsa-miR-143 has been
linked to MPM only once, in a study that showed that its expression is significantly reduced in MPM
as compared to non-neoplastic corresponding tissue [46]. Its functional role in MPM is unknown,
however in other cancers, the decreased expression of has-miR-143 has been shown to promote
EMT, tumor growth, and metastasis [47,48]. Overall, these reports strengthen the findings of our in
silico transcriptomic analysis implicating 30 wound-healing-associated genes in MPM pathogenicity.
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However, it is imperative to investigate the transcriptional expression of these genes in the clinical
setting, taking into account both MPM phenotype and history of asbestos exposure.
5. Conclusions
Conclusively, using data mining and transcriptomic analysis, we have identified a significant
deregulation of 30 wound-healing-related genes in MPM specimens compared to healthy tissues.
We have also demonstrated that these genes are possible targets of the hsa-miR-143, hsa-miR-223, and
the hsa-miR-29 miRNA family members, which contribute in MPM pathobiology as evidenced by
recent studies. Finally, we have identified ITGAV as a novel predictor of overall survival in MPM.
Our results highlight the role of impaired tissue repair in MPM development and should be further
validated experimentally.
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